CytomX Therapeutics Inc’s recent filing unveils that its Chief Financial Officer Ogden Christopher unloaded Company’s shares for reported $28540.0 on Jun 16 ’25. In the deal valued at $2.69 per share,10,614 shares were sold. As a result of this transaction, Ogden Christopher now holds 226,271 shares worth roughly $0.54 million.
Then, Ogden Christopher sold 1,641 shares, generating $4,841 in total proceeds. Upon selling the shares at $2.95, the Chief Financial Officer now owns 199,385 shares.
Before that, BELVIN MARCIA sold 13,884 shares. CytomX Therapeutics Inc shares valued at $37,334 were divested by the SVP, Chief Scientific Officer at a price of $2.69 per share. As a result of the transaction, BELVIN MARCIA now holds 272,252 shares, worth roughly $0.65 million.
Oppenheimer initiated its CytomX Therapeutics Inc [CTMX] rating to an Outperform in a research note published on July 31, 2025; the price target was $7. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in mid May from “a Neutral” to “a Buy”. Piper Sandler revised its rating on May 28, 2024. It rated CTMX as “an Overweight” which previously was an “a Neutral”.
Price Performance Review of CTMX
On Tuesday, CytomX Therapeutics Inc [NASDAQ:CTMX] saw its stock fall -0.84% to $2.37. Over the last five days, the stock has gained 5.33%. CytomX Therapeutics Inc shares have risen nearly 76.87% since the year began. Nevertheless, the stocks have risen 130.10% over the past one year.
How much short interest is there in CytomX Therapeutics Inc?
A steep rise in short interest was recorded in CytomX Therapeutics Inc stocks on 2025-07-15, growing by 3.08 million shares to a total of 23.87 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 20.79 million shares. There was a rise of 12.9%, which implies that there is a positive sentiment for the stock.
